JP2023501457A5 - - Google Patents

Info

Publication number
JP2023501457A5
JP2023501457A5 JP2022526505A JP2022526505A JP2023501457A5 JP 2023501457 A5 JP2023501457 A5 JP 2023501457A5 JP 2022526505 A JP2022526505 A JP 2022526505A JP 2022526505 A JP2022526505 A JP 2022526505A JP 2023501457 A5 JP2023501457 A5 JP 2023501457A5
Authority
JP
Japan
Prior art keywords
composition
administered
subject
dose
gout
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022526505A
Other languages
English (en)
Japanese (ja)
Other versions
JP7821105B2 (ja
JP2023501457A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059377 external-priority patent/WO2021092354A1/en
Publication of JP2023501457A publication Critical patent/JP2023501457A/ja
Publication of JP2023501457A5 publication Critical patent/JP2023501457A5/ja
Application granted granted Critical
Publication of JP7821105B2 publication Critical patent/JP7821105B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022526505A 2019-11-08 2020-11-06 ペグ化ウリカーゼの処方物および用量 Active JP7821105B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962933309P 2019-11-08 2019-11-08
US62/933,309 2019-11-08
PCT/US2020/059377 WO2021092354A1 (en) 2019-11-08 2020-11-06 Formulations and doses of pegylated uricase

Publications (3)

Publication Number Publication Date
JP2023501457A JP2023501457A (ja) 2023-01-18
JP2023501457A5 true JP2023501457A5 (https=) 2023-11-14
JP7821105B2 JP7821105B2 (ja) 2026-02-26

Family

ID=73699416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526505A Active JP7821105B2 (ja) 2019-11-08 2020-11-06 ペグ化ウリカーゼの処方物および用量

Country Status (9)

Country Link
US (1) US20210187081A1 (https=)
EP (1) EP4054531A1 (https=)
JP (1) JP7821105B2 (https=)
CN (2) CN118384281A (https=)
AU (1) AU2020380944A1 (https=)
CA (1) CA3160642A1 (https=)
IL (1) IL292770A (https=)
MX (1) MX2022005506A (https=)
WO (1) WO2021092354A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374963B (es) 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
BR122020023215B1 (pt) 2013-05-03 2022-11-22 Selecta Biosciences, Inc Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
JP7242180B2 (ja) 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5804178A (en) 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
JP3462313B2 (ja) 1995-08-24 2003-11-05 キッコーマン株式会社 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
JP4751556B2 (ja) 2000-02-28 2011-08-17 ジーンシーグス， インコーポレイテッド ナノカプセルカプセル化システムおよび方法
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
WO2003020797A1 (en) 2001-08-30 2003-03-13 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
MXPA06006738A (es) 2003-12-19 2006-08-31 Univ North Carolina Metodos para fabricar micro- y nano-estructuras aisladas utilizando litografia suave o de impresion.
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
KR102601922B1 (ko) 2014-11-05 2023-11-15 셀렉타 바이오사이언시즈, 인크. 안정한 과-포화 상태로 라파마이신을 포함하는 합성 나노담체와 관련된 방법 및 조성물
KR20180120753A (ko) 2016-03-11 2018-11-06 셀렉타 바이오사이언시즈, 인크. Peg화 우리카제의 제제 및 용량
ES3036482T3 (en) * 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
AU2020287627A1 (en) * 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase

Similar Documents

Publication Publication Date Title
JP2023501457A5 (https=)
JP2024102099A5 (https=)
JP6356548B2 (ja) エクセナチドの経口投与用の方法及び組成物
CA3043284C (en) Treatment for fibrosis
JP5222727B2 (ja) タンパク質を経口投与するための方法及び組成物
US11197870B2 (en) Treatment for hepatic fibrosis
JP2020510687A5 (https=)
KR102319078B1 (ko) 궤양성 대장염의 치료용 의약 조성물
JP2011514379A (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
MD3684344T2 (ro) Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
JP2022535121A5 (https=)
CN118384281A (zh) 聚乙二醇化尿酸酶的制剂和剂量
CN121443295A (zh) 治疗前列腺癌的方法
JP2021534208A5 (https=)
US20220192999A1 (en) Use of gold nanoclusters in treating hypercholesterolemia or hypercholesterolemia-associated diseases
TWI901895B (zh) 一種包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－甲酸的醫藥組成物
WO2012106947A1 (zh) 含维生素d和二甲双胍的药物组合物
WO2022162021A1 (en) Verinurad compositions and methods of use
JP2020143037A (ja) 糖尿病合併心不全の治療用医薬組成物
JP2024508334A5 (https=)
EP4599828A1 (en) Pharmaceutical composition for prevention or treatment of nephropathy and/or diabetes mellitus, comprising enavogliflozin
CN112512526B (zh) 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途
Ghosh et al. A review on pharmacological and therapeutic Insight of ozanimod for colon disease in nanostructure
JP2023543131A5 (https=)
TW202517250A (zh) Ｌｐ（ａ）干擾劑化合物之治療用途及劑量